Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise

References

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007; 25: 3007–3013
   PubMed Web of Science ®Google Scholar
• Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59–65
   PubMed Web of Science ®Google Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(Suppl 1)S16–24
   PubMed Web of Science ®Google Scholar
• Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24(Suppl 1)S1–15
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621–632
   PubMed Web of Science ®Google Scholar
• Suarez E, Smith J, Bosch F, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008; 26S: F29–45
   Google Scholar
• Beby-Defaux A, Bourgoin A, Ragot S, et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 2004; 73: 262–268
   PubMed Web of Science ®Google Scholar
• Boulanger JC, Sevestre H, Bauville E, et al. [Epidemiology of HPV infection]. Gynecol Obstet Fertil 2004; 32: 218–223
   PubMedGoogle Scholar
• Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616–1623
   PubMed Web of Science ®Google Scholar
• Dalstein V, Riethmuller D, Sautiere JL, et al. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 2004; 40: 1225–1232
   PubMed Web of Science ®Google Scholar
• Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999; 8: 157–164
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285: 2995–3002
   PubMed Web of Science ®Google Scholar
• Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252–258
   PubMedGoogle Scholar
• Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92: 727–735
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336–1343
   PubMedGoogle Scholar
• Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415–1423
   PubMed Web of Science ®Google Scholar
• Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–428
   PubMed Web of Science ®Google Scholar
• Molano M, Van den BA, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486–494
   PubMed Web of Science ®Google Scholar
• Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 1782–1783
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 3106–3114
   PubMed Web of Science ®Google Scholar
• lääkäriseura Duodecimin ja Suomen kolposkopiayhdistyksen asettama työryhmä. Suomalaisen. Käypä hoito -suositus: Kohdunkaulan, emättimen ja ulkosynnytinten solumuutokset - diagnostiikka, hoito ja seuranta. Duodecim 2006; 122: 1808–1833
   Google Scholar
• Finnish Cancer Registry. http://www.cancerregistry.fi. 2007
   Google Scholar
• Monto K, Nieminen P. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa. Suom Lääkäril 2005; 18-19/2005: 2093–2097
   Google Scholar
• Nieminen P, Kallio M, Anttila A, et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999; 83: 55–58
   Google Scholar
• Paavonen J, Jenkins D, Bosch F, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–2170
   PubMed Web of Science ®Google Scholar
• Paavonen J. Mitä HPV-rokotteilta voidaan odottaa?. Suomen Lääkärilehti 2009; 11: 1017–1021
   Google Scholar
• Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141: 680–689
   PubMed Web of Science ®Google Scholar
• Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810–819
   PubMed Web of Science ®Google Scholar
• Nieminen P, Vuorma S, Viikki M, et al. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG 2004; 111: 842–848
   PubMed Web of Science ®Google Scholar
• Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24(Suppl 3)S3–26/34
   Google Scholar
• Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991–998
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–1565
   PubMed Web of Science ®Google Scholar
• FIGO. (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1)S1–257
   Google Scholar
• Statistics Finland. www.stat.fi. 2008
   Google Scholar
• Hujanen T, Kapiainen S, Tuominen U, et al, Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006 (Healthcare unit costs in Finland 2006). 3/2008, 1–107. 2008. Helsinki, Stakes. Työpapereita
   Google Scholar
• Helsingin ja Uudenmaan airaanhoitopiiri. Hinnasto 2008. (Official price list of Hospital District of Heslinki and Uusimaa). 2008.
   Google Scholar
• Varsinais-Suomen sairaanhoitopiiri. Palveluhinnasto 2008. (Official price list of Hospital District of Southwest Finland, 2008). http:///www.vsshp.fi. 2008
   Google Scholar
• Price SLD, [Finnish Pharmaceutical Data Ltd/Suomen Lääkedata Oy; 2008
   Google Scholar
• Health Outcomes Data Repository. https://crc-limited.co.uk. 2007. Cardiff Research Consortium.
   Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005; 23: 1107–1122
   PubMedGoogle Scholar
• Myers ER, Green S, Lipkus I, Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. (Abstract n° 542 presented at the Twenty-First International Papillomavirus Conference, México City, México. February 20–27). 2004
   Google Scholar
• Rokotuskattavuus Suomessa. (Vaccination coverage in Finland). http://www.ktl.fi/portal/suomi/terveyden_ammattilaisille/rokottaminen/rokotuskattavuus/. 2010. Terveyden ja Hyvinvoinnin Laitos (National Institute for Health and Welfare). 23-2-2010.
   Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247–1255
   PubMed Web of Science ®Google Scholar
• Sosiaali- ja terveysministeriön asetus lääkkeiden hintalautakunnalle tehtävästä hakemuksesta ja hintailmoituksesta. (Guideline for Health Economic Evaluation). 27 Mar. 2009. Sosiaali- ja terveysministeriö (Ministry of Social Affairs and Health). 201/2009. http://www.finlex.fi/fi/laki/alkup/2009/20090201 Accessed 23 Feb. 2010
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479–500
   PubMed Web of Science ®Google Scholar
• @RISK for Excel. Version 4.5.5 (US/English) [Palisade Corporation; 2005
   Google Scholar
• Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 513–517
   PubMedGoogle Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890–907
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88–100
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23: 76–82
   PubMed Web of Science ®Google Scholar
• Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15: 265–302
   PubMed Web of Science ®Google Scholar
• Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(Suppl 1)S97–106
   PubMedGoogle Scholar
• Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18: 3263–3282
   PubMed Web of Science ®Google Scholar
• Harper D, Gall S, Naud P, et al, Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine). Late-breaking abstracts presented for the 39th Annual Meeting of the Society of Gynecologic Oncologists, 9–12 March, Tampa, USA). Gynecol Oncol 2008;109:158
   Google Scholar
• Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol 2008; 198: 261.e1–11
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896–904
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915–1923
   PubMed Web of Science ®Google Scholar
• Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007; 96: 143–150
   PubMed Web of Science ®Google Scholar
• Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604–615
   PubMed Web of Science ®Google Scholar
• Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631–639
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781–789
   PubMed Web of Science ®Google Scholar
• Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37–48
   PubMed Web of Science ®Google Scholar
• Van De Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165: 762–775
   PubMed Web of Science ®Google Scholar
• Lasten rotavirusrokotustyöryhmä. Kansanterveyslaitoksen asettama lasten rotavirusrokotustyöryhmän selvitys. B28/2007. 26-11-2007. Helsinki, Kansanterveyslaitos (National Public Health Institute, Finland). Kansanterveyslaitoksen julkaisuja
   Google Scholar
• Lasten pneumokokkirokotustyöryhmä. Kansanterveyslaitoksen asettama lasten pneumokokkirokotustyöryhmän selvitys. B12/2008. 2008. Helsinki, Kansanterveyslaitos (National Public Health Institute, Finland). Kansanterveyslaitoksen julkaisuja
   Google Scholar
• Bell S, Porter M, Kitchener H, et al. Psychological response to cervical screening. Prev Med 1995; 24: 610–616
   PubMed Web of Science ®Google Scholar
• Lerman C, Miller SM, Scarborough R, et al. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991; 165: 658–662
   PubMed Web of Science ®Google Scholar